T. Rowe Price Associates’s Windtree Therapeutics Inc WINT Stock Holding History

T. Rowe Price Associates’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,009	Closed	-$9K	–	2548
2015 Q4	$9K	Hold	3,009	–	–	﹤0.01%	2510
2015 Q3	$13K	Hold	3,009	–	–	﹤0.01%	2507
2015 Q2	$29K	Buy	3,009 +429	+17%	+$6.02K	﹤0.01%	2521
2015 Q1	$43K	Hold	2,580	–	–	﹤0.01%	2515
2014 Q4	$42K	Hold	2,580	–	–	﹤0.01%	2519
2014 Q3	$66K	Buy	2,580 +1,000	+63%	+$24.1K	﹤0.01%	2505
2014 Q2	$39K	Hold	1,580	–	–	﹤0.01%	2514
2014 Q1	$48K	Hold	1,580	–	–	﹤0.01%	2480
2013 Q4	$50K	Buy	1,580 +357	+29%	+$11.2K	﹤0.01%	2458
2013 Q3	$34K	Hold	1,223	–	–	﹤0.01%	2445
2013 Q2	$26K	Buy	+1,223	New	+$30.1K	﹤0.01%	2423

Other funds holding WINT

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

T. Rowe Price Associates's WINT Position: Q1 2016 in Review

T. Rowe Price Associates sold out of Windtree Therapeutics Inc (WINT) in Q1 2016, closing a stake of 3,009 shares — an estimated $9K sold.

T. Rowe Price Associates first reported a position in WINT in Q2 2013 and held it in 11 quarters. The position peaked at $66K in Q3 2014. 34 funds tracked by Wall St. Rank hold WINT as of Q1 2016.

T. Rowe Price Associates reported no remaining Windtree Therapeutics Inc position as of Q1 2016 after selling out during the quarter.
T. Rowe Price Associates sold 3,009 Windtree Therapeutics Inc shares in Q1 2016, an estimated $9K.
T. Rowe Price Associates first reported a position in Windtree Therapeutics Inc in Q2 2013 and held it in 11 quarters.
T. Rowe Price Associates's Windtree Therapeutics Inc position peaked at $66K in Q3 2014.
34 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q1 2016.

Based on T. Rowe Price Associates's 13F filing for Q1 2016, filed 16 May 2016.